Physical AI Clinical Infrastructure · Class IIa Regulated
Physical AI clinical infrastructure that acquires objective physiological ground truth before inference.
Built on 15 years of clinical deployment across more than 9 million patient episodes.
The Structural Problem
Current AI systems depend on what the patient says. But patients are often unreliable historians - filtered by perception, vocabulary, stoicism, and the limits of self-observation. Clinical inference requires objective physiological data, not narrative.
LLMs are blind and deaf.
A patient describing "gastric pain" may be experiencing gastritis. Or an inferior-wall myocardial infarction. Without a 12-lead ECG and troponin measurement, no AI - regardless of how capable - can reliably distinguish the two.
The reasoning capacity of modern AI has outpaced the quality of the data it reasons on. The bottleneck is not intelligence. It is sensory grounding.
Text-only AI reasons from words alone. "Patient Speak" without sensor data is not clinical input. It is noise dressed as signal - and decisions built on it are structurally unsafe.
A single lab value misses trajectory. The velocity of biomarker change is often more informative than the value itself. Medicine sees snapshots. It should see trajectories.
Doctors carry patient context in their heads. When a doctor is unavailable, the context is lost. A new clinician sees only the file. The system must hold the trajectory.
A New Category
A clinical AI system must do more than reason. It must sense, validate, reason longitudinally, govern, and escalate to a human clinician. This requires more than software. It requires infrastructure.
Existing Approach
Chatbot AI
ZoyeMed Approach
Physical AI
Operational Evidence
Before the architecture matters, the operational record matters. ZoyeMed is the current instantiation of a clinical AI lineage that has been in continuous public-health deployment since 2010.
System Architecture
ZoyeMed is structured as a layered architecture where each component has a distinct function and runs at a different tempo. No single model. No black box. Each layer can refuse, escalate, or block.
A single biomarker value can mislead. Trajectories reveal risk. A proprietary sequence architecture tracks the velocity and acceleration of biomarker change across a patient's full history - detecting adverse trends invisible in single-encounter data. Most preventable adverse clinical events have precursor trends of exactly this kind.
Primary AI inference runs on-device. Patient identifying data is anonymised at the edge - identifiers never reach the inference layer. Cloud round-trip is not required for clinical operation. This is what makes data sovereignty a property of architecture, not policy.
Ground Truth Before Inference
The architecture in motion - through a single clinical scenario. Patient self-report enters the system. Sensor data overrides it. The safety gate escalates. A clinician decides.
Patient presentation begins with self-report. A chatbot would reason from this text alone. ZoyeMed treats it as input - not as ground truth.
"Acidity" is recoded. AI output suppressed pending clinician review.
Remote specialist alerted. Local operator briefed. Emergency referral protocol triggered. Patient routed to nearest interventional cardiology centre. The system does not act autonomously. It surfaces, escalates, and waits for the human.
Longitudinal Intelligence
A single lab value can look reassuring. The trajectory may be dangerous. The system tracks not just where the patient is - but where they are heading, and how fast.
HbA1c, 5.8%. A single measurement. Within the "normal" range. A snapshot model concludes: no action required.
Three months earlier: 5.0%. The velocity is the signal. The patient is moving toward dysglycaemia faster than the threshold is approaching.
A longitudinal model detects this. A snapshot model cannot. Most preventable adverse clinical events have precursor trends of exactly this kind.
Similar pattern: creatinine drift within normal range. SpO₂ baseline shift. Thyroid trajectory across pregnancy. Statin response over 12 weeks. The trajectory carries the diagnosis.
National Health Intelligence
A single ZoyeMed terminal produces individual patient data. A national fleet produces a real-time epidemiological signal - derived from clinically measured ground truth, not survey self-report.
Illustrative. All patient data anonymised at edge before aggregation. Data residency configurable per jurisdiction.
15-Year Clinical Lineage
The architectural choices in ZoyeMed 3.0 are answers to questions asked repeatedly in places where getting it wrong is measured in patients - not quarterly metrics. Nabarangpur. The Sundarbans. Rajasthan. The questions were hard. The answers took time.
Dr. Azim - Founder of the Indian entity - establishes a model to deliver standardised, process-engineered primary care across rural eastern India. First site: Sonamukhi, Bankura district, West Bengal.
Bayesian semantic CDSS developed and deployed across the Glocal network. Cited in peer-reviewed Clinical Decision Support Systems literature as among the more visible CDSS in global operation at the time. Network: 1,100+ hospital beds across four states.
Peer-reviewed CDSS citation 2015The Sundarbans: tidal rivers, island-scattered villages, populations a day's boat-journey from a physician. The architecture learns to function where connectivity is intermittent, power is unreliable, and patient self-report is structurally unreliable.
~100 clinics under India's National Health Mission, Rajasthan. Odisha Digital Dispensary Project in Nabarangpur - one of India's most underdeveloped districts. State MoU for 102 dispensaries across 23 districts. ~500 dispensaries in Madhya Pradesh.
World Rural Healthcare Conference Award 2018 Express Public Health Award 2018Pandemic-capable autonomous terminal with integrated disinfection deployed across Indian states. Five simultaneous international recognitions in a single year - independent validation of operational and clinical credibility.
WEF / Schwab Social Entrepreneur UN Innovation Award Bloomberg New Economy Gamechanger Frost & SullivanComplete re-engineering for edge-first inference, longitudinal multimodal AI, clinical decision support guardrails, FHIR R4 output. PCT patent filed for the longitudinal multimodal model architecture. First 44 commercial units delivered to Mexico.
22,000+ consultations through end-March 2026. 18,224 documented in a published Post-Market Clinical Experience Report. Signed multi-year deployment agreements in Colombia. Malaysia entity and IP registration with MDEC underway.
WHX Dubai 2026 BusinessWire coverageMarket Position
The digital health market has sorted into four operating categories. Each addresses one dimension of clinical care delivery. ZoyeMed is a fifth - a physical AI clinical infrastructure layer that integrates sensing, edge inference, longitudinal intelligence, governance, and institutional deployment.
Category 1
Extends physician reach over video and chat at consumer or enterprise scale. AI as workflow augmentation. Cloud-native, no direct sensing.
Category 2
Validated clinical decision support delivered as regulated software, sitting inside existing clinical infrastructure. No proprietary sensing layer.
Category 3
Class II / FDA-cleared devices with deep edge AI within a single clinical function - handheld ultrasound, guided home examination, continuous monitoring.
Category 4
Physical access points in healthcare-gap settings. Modest modality counts. Deliberate scope discipline.
Category 5 · ZoyeMed
Integrates sensing, on-device inference, longitudinal trajectory modelling, governance, and institutional deployment into one clinical operating system.
A separate sub-category - unbounded consumer autonomous kiosks attempting wide clinical scope without regulation, sensing depth, or CDSS lineage - has produced multiple high-profile closures over 2023–24. The full landscape analysis, including a thirteen-platform seven-axis comparison, is available in the Technical White Paper under NDA.
Deployment Model
ZoyeMed deploys as a fleet. Typical deployments begin at 100+ units. Per-client configuration handles all jurisdiction-specific compliance requirements at the governance layer - without branching the codebase.
For Ministries of Health and national public-health agencies. Extend clinical access into underserved geographies while building a real-time epidemiological intelligence layer over the deployment.
Discuss National Programme →For hospital networks and integrated health systems. Distribute diagnostic depth into spoke catchments while preserving central clinical authority and audit.
Discuss Network Deployment →For health insurers and payer organisations. Replace self-reported health declarations with objective sensor-derived data. Detect risk earlier. Price members on what is - not what is reported.
Discuss Payer Integration →For industrial, occupational health, and corporate networks. Deploy clinical-grade health monitoring at industrial scale - across mines, factories, oilfields, smart cities, and large corporate campuses.
Discuss On-Site Deployment →For technical reviewers, regulatory teams, and integration partners. The full technical disclosure - covering longitudinal multimodal model architecture, safety gate design, PHI handling, and interoperability - is available under NDA.
Request Technical Disclosure →Mexico - 44 units delivered under institutional programme; multi-phase contract up to 300 units; 18,224 PMCF-documented consultations through Feb 2026. | Colombia - Signed agreement for annual deployments over a three-year term; first ZoyeMed 3.0 unit delivered to Bogotá. | Malaysia - Entity and IP registration with MDEC underway; in-country data residency–compliant infrastructure confirmed.
Evidence & Research
Documents are tiered by sensitivity. Public materials are downloadable directly. Technical materials require email-verified institutional access. Commercial and IP materials require an enterprise briefing call.
The clinical rationale for Physical AI. Covers the Snapshot Fallacy, the safety gate, longitudinal multimodal modelling, and evidence-based prescribing democratisation. Grounded in 15 years and 9 million patient outcomes.
↓ Download PDF →A practice-derived replacement for the century-old Alma-Ata tier classification. Two axes - acuity and intervention dependency - generate four operationally coherent quadrants with distinct planning implications.
Thirteen-platform competitive analysis using a seven-axis framework. Includes Post-Market Clinical Experience Report summary covering 18,224 documented consultations. Available to institutional reviewers with verified corporate email.
Explore the ZoyeMed 3.0 terminal in 3D. Sensor positioning, operator workflow, footprint, integration ports. Available to institutional reviewers with verified corporate email.
The full PMCF report covering 18,224 consultations. Patient-level safety, operational performance, and AI-clinician concordance data. Released after a discovery call and NDA execution.
Unit economics, deployment scaling, multi-country revenue model, capital requirements. Released after a qualification call and NDA execution. Not delivered via form.
Multimodal fusion, sequence architecture, sufficiency gating, agentic human-in-the-loop orchestration. For qualified technical, regulatory, or clinical reviewers under signed NDA.
Enterprise Engagement
For governments, hospital networks, insurers, and public-health systems. Typical deployments begin at 100+ units. Qualified partners receive full technical disclosure, PMCF report, and financial model under NDA.